Islet G-protein coupled receptors:therapeutic potential for diabetes by Persaud, Shanta J.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.coph.2017.08.001
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Persaud, S. J. (2017). Islet G-protein coupled receptors: therapeutic potential for diabetes. Current Opinion in
Pharmacology, 37, 24-28. https://doi.org/10.1016/j.coph.2017.08.001
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Manuscript Details
Manuscript number COPHAR_2017_44
Title Islet G-protein coupled receptors: therapeutic potential for diabetes
Short title Islet GPCRs and diabetes therapy
Article type Review article
Abstract
The incidence of type 2 diabetes (T2D) is increasing at an alarming rate, which is imposing substantial healthcare and
economic burdens worldwide. T2D can be treated by a range of drugs, but there is a need to identify additional
therapeutic options. Human islets express nearly three hundred G-protein-coupled receptors (GPCRs), which could be
targeted for the treatment of T2D. However, to date, the GLP-1 receptor is the only islet GPCR for which agonists are
in current clinical use. This review explores pharmaceutical development of drugs that activate individual or multiple
beta-cell GPCRs and explains how our knowledge of GPCR expression by human islets may inform direction on novel
GPCR targets.
Corresponding Author SJ Persaud
Order of Authors SJ Persaud
Submission Files Included in this PDF
File Name [File Type]
Highlights.docx [Highlights]
Persaud.docx [Manuscript File]
Conflicts of interest.docx [Conflict of Interest]
To view all the submission files, including those not included in the PDF, click on the manuscript title on your EVISE
Homepage, then click 'Download zip file'.
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 Type 2 diabetes (T2D) is a major healthcare concern.
 G-protein-coupled receptor (GPCR) ligands are used to treat a range of diseases.
 Human islets express nearly three hundred GPCRs.
 Only one islet GPCR is currently the target of a clinically used T2D therapy.
 Pharmaceutical companies are developing T2D therapies that activate islet GPCRs. 
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Abstract (100-120 words)
The incidence of type 2 diabetes (T2D) is increasing at an alarming rate, which is imposing 
substantial healthcare and economic burdens worldwide. T2D can be treated by a range of 
drugs, but there is a need to identify additional therapeutic options. Human islets express 
nearly three hundred G-protein-coupled receptors (GPCRs), which could be targeted for the 
treatment of T2D. However, to date, the GLP-1 receptor is the only islet GPCR for which 
agonists are in current clinical use. This review explores pharmaceutical development of drugs 
that activate individual or multiple -cell GPCRs and explains how our knowledge of GPCR 
expression by human islets may inform direction on novel GPCR targets.
Introduction
G-protein-coupled receptors (GPCRs) have proven to be tractable targets for therapeutic 
intervention. For example, drugs targeting beta-2 adrenergic receptors on bronchial smooth 
muscle have been used to treat asthma for nearly 50 years [1], and antagonists of the AT1 
angiotensin receptors were developed in the 1990s as effective anti-hypertensive drugs [2]. 
Over 800 human GPCR sequences have been identified [3] and it has been estimated that 
ligands targeting the GPCR superfamily account for 30-50% of all drugs that are in clinical use 
[4,5]. In fact, analysis of drugs that were approved by the US Food and Drug Administration 
over the three decades from 1982-2010 indicated that GPCRs are the largest class of targets 
for the development of new pharmaceutical products, with approximately 36% of all drugs 
reviewed acting at GPCRs [6]. In addition, 30% of the drugs with the highest global sales in 
2010 targeted GPCRs [6].
Overview of therapies for Type 2 diabetes
Diabetes is a growing health concern and the incidence is continuing to increase at an 
alarming rate: the latest International Diabetes Federation data from Nov 2015 indicate that 
415 million people worldwide had diabetes, and this is predicted to reach 642 million by 2040. 
Approximately 90% of people with diabetes have type 2 diabetes (T2D), which can be treated 
with a variety of drugs that directly stimulate insulin secretion from islet -cells, improve 
sensitivity of peripheral tissues to circulating insulin, promote excretion of excess glucose in 
the urine or delay carbohydrate digestion (Table 1). The current front-line therapy for T2D, 
metformin, is an effective, inexpensive and well tolerated therapy, but there is a requirement 
for additional therapies when metformin is no longer capable of maintaining appropriate 
glucose homeostasis. 
Of the many therapies in clinical use for T2D only GLP-1 analogues, which have been 
introduced in the last decade, are GPCR ligands. These drugs mimic the insulin stimulatory 
and glucagon inhibitory actions of the enteroendocrine cell-derived peptide GLP-1, which has 
a half-life of only 1-2 minutes. The GLP-1 analogues are long-acting through modifications of 
the peptide sequence. For example, exenatide (Byetta) lacks the N-terminal alanine at position 
2 that is recognised by DPP4, a protease that cleaves and inactivates native GLP-1, and 
liraglutide (Victoza) contains a fatty acid residue to allow binding to albumin to extend its 
circulating half life. DPP4 inhibitors, which prevent removal of the N-terminal dipeptide from 
GLP-1 and the other incretin hormone GIP, are also used clinically as insulin secretagogues. 
The increased circulating concentrations of incretin peptides with use of DPP4 inhibitors leads 
to enhanced signalling via their specific GPCRs on islet -cells, both of which are coupled to 
elevations in intracellular cyclic AMP, thus promoting insulin exocytosis. The GLP-1 analogues 
act directly at GLP-1 receptors to have the same effect as endogenous GLP-1, but with 
prolonged duration of action. The currently prescribed GLP-1 analogues are reported to 
promote -cell mass expansion in rodents [7], but similar beneficial effects have not been 
identified in humans [8].
Targeting islet GPCRs to develop novel therapies for Type 2 diabetes
While it is clear that there are numerous classes of drugs currently available to treat T2D 
(Table 1), only a minority of patients achieve full glycaemic control and there are potentially 
life-threatening side effects associated with some therapies [9]. In particular, there are 
concerns about the safety of therapies that are targeted at islet -cells to promote increased 
insulin secretion to combat the insulin resistance that occurs in T2D. For example, 
sulphonylureas may induce dangerous hypoglycaemia and their long term use has been 
associated with increased incidence of coronary heart disease [10]. In addition, it has been 
proposed that prolonged sulphonylurea use is associated with progressive deterioration in 
beta-cell function [11], which could exacerbate the underlying pathology of T2D where there 
are reductions in -cell mass [12]. The FDA issued a safety communication in 2013 that use 
of GLP-1 analogues has been linked to acute pancreatitis [13], but a recent meta-analysis of 
randomised clinical trials using a range of GLP-1 receptor agonists indicated that the incidence 
of pancreatitis was not increased with their use [14]. Nonetheless, the analysis did indicate an 
increased risk of cholelithiasis with GLP-1 analogues [14], and in 2016 an FDA warning was 
issued on severe and disabling joint pain associated with DPP4 inhibitor use [15]. These 
limitations in drug safety profiles and efficacy mean that the search for improved therapies is 
ongoing: since GPCRs have proven to be a successful target class for many indications [6] 
and GLP-1 mimetics now account for over 9% of the total diabetes market [16], pharmaceutical 
companies have been investigating the utility of targeting other islet GPCRs.
Single GPCR targets
Several -cell-targeted T2D drugs have been under development in the past few years and 
there has been a focus on insulin secretagogue therapies that act at Gs- or Gq-coupled 
receptors. For example, FFAR1 (GPR40) is a Gq-coupled GPCR that is expressed by islet -
cells and also by the enteroendocrine L-cells that secrete GLP-1. This makes it a target of 
interest since selective agonists would be expected to stimulate insulin secretion through 
direct effects at -cells or via indirect action to increase GLP-1 release, and GLP-1 also acts 
centrally to reduce food intake. Synthetic FFAR1 agonists have been effective in improving 
glucose tolerance in rodents [17,18], but development of FFAR1 agonists as T2D therapeutics 
has largely been unsuccessful and several potential candidates that entered clinical trials 
(Table 2) have been discontinued because of toxicity issues or unacceptable adverse effects. 
Nonetheless, phase I development is currently ongoing for some FFAR1 ligands (Table 2) and 
use of one of these (LY 2922470) in people with T2D has indicated that it exerts glucose 
lowering effects without hypoglycaemia [19]. GPR119, which is a Gs-coupled GPCR that is 
activated by the arachidonic metabolite N-arachidonoylethanolamine (AEA), has also been 
explored as a target for T2D therapy since this receptor is also expressed by -cells and L-
cells. GPR119 agonists stimulate secretion of GLP-1 and insulin and they have glucose 
lowering effects in rodents [20]. However, it has recently become apparent through studies 
with -cell-specific deletion of GPR119 that the presence of this receptor on -cells is not 
required for GPR119 agonist-induced improvements in insulin secretion and glucose tolerance 
in mice [21]. Similar to FFAR1 agonists, apparently promising drugs that target GPR119 to 
improve glucose homeostasis in rodents have failed to progress beyond phase II clinical trials 
because of adverse effects or unfavourable study results (Table 2; [22]). 
Multiple GPCR targets
An alternative strategy for T2D therapeutic development has been to antagonise the effects 
of the islet-derived peptide, glucagon, which acts at its GPCR on hepatocytes to stimulate 
glycogenolysis and gluconeogenesis [23]. Antagonism of these effects will therefore 
ameliorate the hyperglycaemia that is evident in T2D. Paradoxically, however, agonism of 
glucagon receptors could also be therapeutically viable since glucagon acts in a paracrine 
manner to promote insulin secretion and it also induces lipolysis and has anorexigenic effects, 
which are advantageous in T2D where the majority of individuals are overweight or obese. 
Given the effects of glucagon to increase hepatic glucose output glucagon receptor agonists 
on their own are not an appropriate therapeutic option. However, glucagon and GLP-1 
chimeric peptides have been developed that act as co-agonists at glucagon and GLP-1 
GPCRs, and these have been effective in reducing fat mass and improving glucose tolerance 
in obese mice [24]. There has been interest from pharmaceutical companies to harness these 
beneficial effects through the development of therapeutics that activate both glucagon and 
GLP-1 receptors. Some of these are currently being assessed in phase I or II clinical trials 
(Table 2), but patient recruitment has recently been suspended for at least one of these dual 
agonists (HM 12525A) pointing to potential problems with the use of this class of therapy. The 
reasons for suspension of the trial are not clear, but the effect of glucagon agonism at the liver 
to promote hyperglycaemia may be a contributory factor. Another strategy for dual agonist 
development has been to combine the insulin secretagogue effects of the incretins by 
generating single molecule drugs that activate both GLP-1 and GIP receptors, the so-called 
“twincretin” approach [25]. Both of these receptors are Gs-coupled to promote insulin secretion 
so activation of both islet incretin receptors should produce additive or synergistic glucose 
lowering effects. However, clinical trials with dual GLP-1 and GIP receptor agonists (Table 2) 
have not produced encouraging results and there currently appears to be no further activity in 
this area. The feasibility of polyagonists that activate GLP-1, GIP and glucagon receptors is 
being tested, with promising results in rodents, but clinical data are not yet available [26]. 
GPCR expression by human islets
Despite the appeal of exploiting GPCRs for development of novel T2D therapies, clinical trials 
have so far been based on very few islet GPCRs (Table 2), and the outcomes to date, as 
outlined above, have been disappointing. This lack of success may be because there is very 
limited scope in the receptors being targeted – so far potential therapies have been largely 
based on those activating FFAR1, GPR119 or incretin receptors, as indicated in Table 2. 
However, it is now apparent that human islets express mRNAs encoding 293 of the 384 
functional non-odorant GPCRs encoded in the human genome [27], so there is plenty of 
opportunity for looking beyond the ‘usual suspects’. One interesting candidate that was 
identified by this GPCRome screening is the Gq-coupled receptor GPR75, which is activated 
by CCL5 (chemokine (C-C motif) ligand 5). CCL5 has direct effects on isolated mouse and 
human islets to potentiate glucose-induced insulin secretion and it also improves glucose 
tolerance in mice [28]. CCL5 is not a suitable candidate for diabetes therapy as it also activates 
chemokine receptors implicated in -cell destruction, but development of selective GPR75 
agonists may be a promising route in improving therapeutic options for T2D. Another human 
islet GPCR that is currently receiving attention as a potential target for T2D therapy is GPR55, 
a putative cannabinoid receptor, which is coupled to direct stimulation of insulin secretion in 
vitro [29,30], and improvement in glucose tolerance in vivo in an incretin receptor-dependent 
manner [31]. 
Much of the research carried out on function of islet GPCRs in vitro has been performed using 
rodent islets and, by necessity, all basic science in vivo studies are performed using rodent 
models. There is usually a close correlation between the rodent and human experimental data, 
but there are occasionally divergences and it is obviously essential that data generated in mice 
and rats are translatable to the human situation. A recent study has indicated that while there 
is close correlation between the most abundantly expressed human and mouse islet GPCRs 
there are 63 mouse islet GPCRs that are not expressed by human islets [32]. This highlights 
the importance of the human islet GPCRome in defining clinically relevant therapeutic targets.   
Conclusions
This short review has focused on islet GPCRs as possible targets for treating T2D, but, of 
course, this is an over-simplification: while islets express nearly three hundred GPCRs these 
receptors are not confined to islets, but are expressed by many other tissues too. In some 
respects this can be useful. For example, the GLP-1 analogues that are currently used to treat 
T2D act directly at islet -cells to stimulate insulin secretion, but they have additional glucose 
regulatory effects through hypothalamic signalling to reduce food intake and they also act at 
the gut to delay gastric emptying. In addition, the FFAR1 and GPR119 agonists that have 
been under development for T2D are attractive because they are expressed by -cells and L-
cells, which should lead to improved glucose tolerance through stimulation of insulin release 
both directly and indirectly via enhanced GLP-1 secretion. However, as investigations 
progress on novel islet GPCR candidates it will be important to consider potential contra-
indications that could arise through off-target effects at other tissues.
It is also important that the capacity of drugs to promote the survival and proliferation of insulin 
producing -cells is fully considered when deciding which potential therapeutics to take 
forward to clinical trial, as without maintained -cell mass people with T2D will eventually 
require exogenous insulin to maintain their blood glucose levels in the appropriate range. This 
can be problematic as while it is easy to quantify insulin secretagogue effects of drugs in 
humans there are currently no standardised methods for non-invasive quantification of human 
-cell mass in vivo. Surrogate measurements of -cell mass in humans suggest that the 
promising effects of GLP-1 analogues to promote -cell proliferation and protect against 
apoptosis in rodents do not occur in humans, so there is plenty of scope to identify GPCR 
ligands that not only potentiate glucose-stimulated insulin release but also promote the 
survival and proliferation of insulin-producing -cells.
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Table 1: Drug families currently used for treating Type 2 diabetes and their modes of 
action.
The table includes the classes of non-insulin therapies available for treatment of Type 2 
diabetes, together with brief information on their modes of action. Examples of clinically 
prescribed drugs are provided for each family.
Main effect Drug family Mode of action First 
introduced
Sulphonylureas
Glibenclamide (Daonil) 
Glimepiride (Amaryl)
Close -cell KATP channels leading 
to decreased K+ efflux, membrane 
depolarisation, Ca2+ influx and 
enhanced insulin secretion.
1950s
Glinides 
Nateglinide (Starlix) 
Repaglinide (Prandin)
Same mode of action as 
sulphonylureas, but glinides are 
shorter acting.
1990s
GLP-1 analogues
Exenatide (Byetta)
Liraglutide (Victoza)
Have the same actions as the 
short-lived incretin peptide GLP-1 
to activate -cell GLP-1 receptors, 
increase cyclic AMP levels and 
activate protein kinase A to 
increase insulin secretion.
2000sIncrease 
insulin 
secretion
DPP4 inhibitors
Vildagliptin (Galvus)
Sitagliptin (Januvia)
Inhibit the proteolytic action of 
DPP4, thus increasing levels of 
endogenous GLP-1 (and GIP), 
which can stimulate insulin 
secretion through elevations in 
cAMP (as for GLP-1 analogues).
2000s
Biguanides
Metformin 
(Glucophage)
Activate AMP kinase in the liver to 
reduce gluconeogenesis. 
1950s
Increase 
insulin 
sensitivity
Thiazolidinediones
Pioglitazone (Actos)
Bind to nuclear PPAR receptors 
to stimulate transcription of 
anabolic genes, resulting in 
enhanced glucose and fatty acid 
uptake into adipocytes.
1990s
Increase 
glucose 
excretion
SGLT2 inhibitors
Canagliflozin 
(Invokana)
Dapagliflozin (Forxiga)
Inhibit SGLT2 transporters in the 
kidney proximal tubules to block 
glucose re-uptake into the blood 
so excess glucose is excreted in 
the urine.
2010s
Delay 
carbohydrate 
digestion
-glucosidase inhibitors
Acarbose (Glucobay)
Miglitol (Glyset)
Competitively inhibit -
glucosidase enzymes on intestinal 
enterocytes toreduce cleavage of 
oligosaccharides. This delays 
completion of carbohydrate 
digestion so reduces elevations in 
glucose after a meal.
1990s
Table 2: Islet GPCR agonists that have been used in clinical trials for Type 2 diabetes.
The table includes a non-exhaustive list of agonists developed by a range of pharmaceutical 
companies that target GPCRs expressed by human islets. It also includes the highest 
development phase of clinical testing for each drug.
Target Drug Highest 
Development 
Phase
Pharmaceutical 
Company
SINGLE 
AGONISTS
AMG-837 Phase I Amgen
ASP-4178 Phase I Astellas
LY 2881835 Phase I Eli Lilly
P 11187 Phase I Piramal Enterprises
Fugeliefan Phase I Jiangsu Hengrui
LY 2922470 Phase I Eli Lilly
JTT 851 Phase II Japan Tobacco
FFAR1 (GPR40)
TAK-875 Phase III Takeda
BMS 903452 Phase I Bristol-Myers Squibb
MBX 2982 Phase II CymaBay Therapeutics
PSN821 Phase II Prosidion
LEZ 763 Phase II Novartis
GPR119
DS 8500 Phase II Daiichi Sankyo Company
CO-AGONISTS
ZP 2929 Phase I Zealand Pharma
MK 8521 Phase II Merck & Co
HM 12525A Phase I Janssen 
Pharmaceuticals
LY 2944876 Phase II Eli Lilly
GLP-1 receptor 
and glucagon 
receptor
MEDI-0382 Phase II MedImmune
SAR 438335 Phase I Sanofi
RG 7697 Phase II RocheGLP-1 receptor 
and GIP receptor NN9709 Phase II Novo Nordisk
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